Will Garner

1.3k total citations · 1 hit paper
30 papers, 772 citations indexed

About

Will Garner is a scholar working on Infectious Diseases, Virology and Surgery. According to data from OpenAlex, Will Garner has authored 30 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 14 papers in Virology and 8 papers in Surgery. Recurrent topics in Will Garner's work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). Will Garner is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). Will Garner collaborates with scholars based in United States, United Kingdom and Germany. Will Garner's co-authors include Anton Pozniak, Kirsten White, Erin Quirk, Andrew Cheng, Andrea Antinori, Hans-Jürgen Stellbrink, Paul E. Sax, Jihad Slim, Edwin DeJesus and Devi SenGupta and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Will Garner

27 papers receiving 761 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Will Garner United States	12	543	376	209	149	137	30	772
Peter Gute Germany	18	868 1.6×	688 1.8×	216 1.0×	45 0.3×	65 0.5×	35	1.2k
Barry Schmetter United States	10	532 1.0×	398 1.1×	89 0.4×	87 0.6×	53 0.4×	10	718
Heribert Knechten Germany	15	512 0.9×	435 1.2×	117 0.6×	42 0.3×	58 0.4×	44	691
Carlos Zala Argentina	17	693 1.3×	515 1.4×	309 1.5×	49 0.3×	58 0.4×	36	905
Jorge Benetucci Argentina	15	417 0.8×	354 0.9×	183 0.9×	35 0.2×	58 0.4×	35	646
C. Lamotte France	13	563 1.0×	513 1.4×	89 0.4×	17 0.1×	65 0.5×	25	645
P. de Truchis France	10	351 0.6×	251 0.7×	147 0.7×	22 0.1×	41 0.3×	20	589
David A. Cooper Australia	9	320 0.6×	237 0.6×	195 0.9×	57 0.4×	119 0.9×	12	578
Birgit Thorup Røge Denmark	13	478 0.9×	359 1.0×	174 0.8×	29 0.2×	98 0.7×	30	682
Pilar García‐Gascó Spain	15	418 0.8×	267 0.7×	161 0.8×	29 0.2×	439 3.2×	19	833

Countries citing papers authored by Will Garner

Since Specialization

Citations

This map shows the geographic impact of Will Garner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Garner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Garner more than expected).

Fields of papers citing papers by Will Garner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Will Garner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Garner. The network helps show where Will Garner may publish in the future.

Co-authorship network of co-authors of Will Garner

This figure shows the co-authorship network connecting the top 25 collaborators of Will Garner. A scholar is included among the top collaborators of Will Garner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Will Garner. Will Garner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kelly, Déirdre, Binita M. Kamath, Emmanuel Gonzalès, et al.. (2025). Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study. Digestive and Liver Disease. 57. S69–S69.

D’Antiga, Lorenzo, Richard J. Thompson, Simon Horslen, et al.. (2025). The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis: data from MARCH/MARCH-ON. Digestive and Liver Disease. 57. S67–S68.

Kamath, Binita M., Will Garner, Pamela Vig, et al.. (2022). Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. The Journal of Pediatrics. 252. 68–75.e5. 15 indexed citations

Loomes, Kathleen M., Robert H. Squires, Déirdre Kelly, et al.. (2022). Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study. Hepatology Communications. 6(9). 2379–2390. 39 indexed citations

Gonzalès, Emmanuel, Winita Hardikar, Michael Stormon, et al.. (2021). Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. The Lancet. 398(10311). 1581–1592. 103 indexed citations

Rizzardini, Giuliano, Andrea Gori, Celia Miralles, et al.. (2019). Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. AIDS. 33(10). 1583–1593. 6 indexed citations

White, Kirsten, Will Garner, Joseph J. Eron, et al.. (2018). Repeat testing of low-level HIV-1 RNA. AIDS. 32(8). 1053–1057. 1 indexed citations

Wohl, David A., Amanda Clarke, Franco Maggiolo, et al.. (2018). Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 11(5). 561–573. 41 indexed citations

Sax, Paul E., Anton Pozniak, Marisa Montes, et al.. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. 390(10107). 2073–2082. 278 indexed citations breakdown →

10.

Mills, Anthony, Will Garner, Anton Pozniak, et al.. (2015). Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. Patient. 8(4). 359–371. 11 indexed citations

11.

Lunzen, Jan van, Andrea Antinori, Calvin Cohen, et al.. (2015). Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults. AIDS. 30(2). 251–259. 27 indexed citations

12.

Garner, Will, et al.. (2015). Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials. Clinical Infectious Diseases. 62(7). 929–934. 2 indexed citations

13.

Cohen, Calvin, Benoît Trottier, Stefan Eßer, et al.. (2015). Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care. 28(3). 401–408. 17 indexed citations

14.

Gathe, Joseph, José Ramón Arribas, Jan van Lunzen, et al.. (2015). Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. Patient. 8(5). 445–454. 11 indexed citations

15.

Reeves, Iain, et al.. (2014). Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials. Journal of the International AIDS Society. 17(4S3). 19807–19807.

16.

Arribas, José Ramón, et al.. (2014). Simplification to Stribild vs continuation of RTV‐boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐PI subgroup analysis. Journal of the International AIDS Society. 17(4S3). 19805–19805. 3 indexed citations

17.

Pozniak, Anton, Martin Markowitz, Anthony Mills, et al.. (2014). Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. The Lancet Infectious Diseases. 14(7). 590–599. 75 indexed citations

18.

Stellbrink, Hans‐Juergen, Andrea Antinori, Anton Pozniak, et al.. (2014). Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis. Journal of the International AIDS Society. 17(4S3). 19793–19793. 6 indexed citations

19.

Nelson, Mark, Richard Elion, C Cohen, et al.. (2013). Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies. HIV Clinical Trials. 14(3). 81–91. 46 indexed citations

20.

Prakash, Chandra, et al.. (1974). Inhibition of DNA polymerases from RNA tumor viruses by tilorone and congeners: Site of action. Biochemical Pharmacology. 23(23). 3259–3265. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact